Navigation Links
Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
Date:9/21/2007

ngoing study, the company anticipates filing an NDA for TREANDA in patients with indolent NHL who are refractory to rituximab in the fourth quarter of 2007. In addition, Cephalon is studying TREANDA in combination with rituximab in patients with relapsed indolent and mantle cell NHL. The company anticipates that results from studies of TREANDA as monotherapy and in combination will be presented at medical meetings later this year.

Upon FDA acceptance of the company's NDA filing of TREANDA for CLL, the company will make a $15 million milestone payment to former shareholders of Salmedix.

About TREANDA

TREANDA is a rationally designed purine analog/alkylator hybrid. Preclinical data demonstrate that TREANDA induces rapid, sustained single- and double-strand DNA damage, which results in apoptosis, or programmed cell death, in the tumor. TREANDA also induces mitotic checkpoint inhibition, which results in non-apoptotic cell death. TREANDA causes DNA disruption that is both extensive and durable exhibiting a low level of cross-resistance to other cytotoxic agents. The dual-effect of the anti-tumor activity of TREANDA may be attributable to its unique chemical design.

Cephalon holds exclusive rights to market and develop TREANDA in the United States. TREANDA is licensed from Astellas Deutschland GmbH. Bendamustine HCl, the active ingredient in TREANDA, is marketed in Germany by Astellas' licensee, Mundipharma International Corporation Limited, under the tradename RIBOMUSTIN(R). In Germany, RIBOMUSTIN is indicated as a single-agent or in combination with other anti-cancer agents for indolent NHL, multiple myeloma, and CLL. SymBio Pharmaceuticals Ltd holds exclusive rights to market and sell bendamustine HCl in Asia.

About Cephalon Oncology

Cephalon Oncology is a strategic business unit focused on the development and commercialization of oncology products and resources for patients and healthcare providers. The Cephalon Oncology portfolio
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. A Versatile Power Supply for All Electrophoresis Applications
2. Highest Possible Transformation Efficiencies for High-Throughput Applications
3. Unique DNA Polymerase Formulation Excels in a Broad Range of PCR Applications
4. High-Throughput System Generates Ultra-Pure PCR Products Suitable for All Applications
5. An Assessment of the Eppendorf twin.tec plate performance in PCR* applications
6. Principles and applications of electrical cell fusion
7. Eppendorf Electroporation Application Notes Your participation is highly welcome !!!
8. Optimizing Büchi® Rotary Evaporator Applications
9. Principles and applications of electrical cell fusion
10. Eppendorf Electroporation Application Notes Your participation is highly welcome !!!
11. Optimizing Büchi® Rotary Evaporator Applications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... The science of light and how ... more than 200 primary students in a traveling program ... of Otago Physics Department and funded by an ... of the university’s OSA/SPIE Student Chapter visited six primary ... children from small, rural schools hands-on lessons in optics ...
(Date:11/21/2014)... November 20, 2014 The ... Chassis, Oligos, Enzymes, Cloning kits), Technology (Bioinformatics, ... (Biofuels, Pharmaceuticals, Biomaterials, Bioremediation) - Global Forecast ... market drivers, threats, opportunities, and challenges. , ... figures spread through 185 pages and in-depth ...
(Date:11/21/2014)... Texas (PRWEB) November 21, 2014 ... Sodium Ferrocyanide Industry” is a professional and in-depth ... provides Sodium ferrocyanide information, like its definition, ... as industry overview. This report covers the international ... as global (such as the US, Europe, Asia, ...
(Date:11/21/2014)... SAN DIEGO , Nov. 20, 2014  Cytori Therapeutics ... Marc Hedrick , M.D. will present live at VirtualInvestorConferences.com ... 4, 2014 TIME:    11:15 am PT / 2:15 ... this URL into your browser,s address bar: http://bit.ly/1B2KGaL ... time and receive event updates. This will ...
Breaking Biology Technology:Optics and photonics outreach programs share science, spark fascination with light 2Optics and photonics outreach programs share science, spark fascination with light 3Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 2Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 3Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 4Sodium Ferrocyanide Market: Analysis for Global & China Regions Development Trends Available at DeepResearchReports.com 2Sodium Ferrocyanide Market: Analysis for Global & China Regions Development Trends Available at DeepResearchReports.com 3Cytori Therapeutics to Provide Corporate Update and Investor Presentation on December 4 through a Live, Interactive Webcast 2Cytori Therapeutics to Provide Corporate Update and Investor Presentation on December 4 through a Live, Interactive Webcast 3Cytori Therapeutics to Provide Corporate Update and Investor Presentation on December 4 through a Live, Interactive Webcast 4
... 12 Odyssey Thera, Inc.,announced today that the ... No. 7,306,914, entitled "Protein-fragment Complementation,Assays (PCA) in whole ... infectious disease and gene therapy." This is the,twelfth ... The patent describes a method for detecting protein-protein,interactions ...
... "Rolling" NDA for Intravenous Iclaprim in cSSSI; Electronic Submission of ... First Modules due Before ... ARPN) announced today the enrolment and dosing of the first ... the treatment,of hospital-acquired pneumonia (HAP) / ventilator-associated pneumonia,(VAP) / healthcare-associated ...
... (Nasdaq:,INSM), today announced that it has been awarded ... (MDA). The grant is expected to cover a,substantial ... 24-week,Phase 3 enabling trial in patients with Myotonic ... biopharmaceutical company with extensive,expertise in biologics and orphan ...
Cached Biology Technology:Odyssey Thera Granted U.S. Patent for Animal Imaging 2First Patients Enrolled in Phase II Trial With Intravenous Iclaprim in HAP/VAP/HCAP 2First Patients Enrolled in Phase II Trial With Intravenous Iclaprim in HAP/VAP/HCAP 3First Patients Enrolled in Phase II Trial With Intravenous Iclaprim in HAP/VAP/HCAP 4First Patients Enrolled in Phase II Trial With Intravenous Iclaprim in HAP/VAP/HCAP 5Insmed Awarded $2.1 Million by Muscular Dystrophy Association 2Insmed Awarded $2.1 Million by Muscular Dystrophy Association 3
(Date:11/4/2014)... study examining only marketing directed at children on ... has found that the majority of black, middle-income ... marketing tactics. , Authored by Arizona State University ... is the first to examine the use of ... fast food restaurants and its relationship to demographics. ...
(Date:11/3/2014)... -- Research and Markets has announced the addition ... and Companies" to their offering. This ... have already started to play an important role in the ... old fashioned bone marrow transplants. Role of cells in drug ... a part of medical practice. Stem cells are ...
(Date:11/2/2014)... , James Dacey explores the ways in which physicists ... innovations from the lab into the commercial market. , ... companies as they move from prototype to product is ... physics-based inventions are usually far from market-ready when initially ... lot more complicated than had been originally thought. , ...
Breaking Biology News(10 mins):Fast food marketing for children disproportionately affects certain communities 2Fast food marketing for children disproportionately affects certain communities 3Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 2Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 3The 'valley of death' facing physics start-ups 2
... lobe dementia ,Frontal lobe dementia (Frontotemporal Dementia, FTD) ... is the form of dementia that occurs most frequently in ... in the frontal lobe where large numbers of brain cells ... part of the brain and constitutes about 30% of the ...
... J. Craig Venter, Energy Bioscience Institute,s Chris Somerville ... Department of Energy Joint Genome Institute (DOE JGI) ... March 25-27, 2009 in Walnut Creek, Calif. ... of renewable energy strategies, biomass conversion to biofuels, ...
... GAINESVILLE, Fla. Older, active people who have a drink ... according to a report today from a University of Florida ... and Drugs . Although people 50 or older in ... they performed worse on special tests after having moderate amounts ...
Cached Biology News:Blood test predicts chance of dementia 2Venter, Somerville and Church highlight DOE/JGI genomics of energy and environment meeting 2After a few drinks, older adults more impaired than they think 2After a few drinks, older adults more impaired than they think 3
... 48° Fixed Angle Polypropylene Rotor ... Series, IEC Centra CL3/CL3R** and Centra-MP4/MP4R*. ... quiet operation. /MP4, ,EXCLUSIVE polypropylene rotor ... can be repeatedly autoclaved. Polypropylene ...
The 891 45° Fixed Angle Rotor is designed to provide aerosol containment and can be removed from a centrifuge (seal entact) and opened under an environmental hood....
... The Xcise is a powerful technology ... throughput proteome analysis. High quality sample ... untrained user. , The Xcise is a ... for high throughput proteome analysis. It combines ...
Extra Large bottle for hybridization 300 x 70mm...
Biology Products: